ArticleEMBO reports2026
UHRF1 overexpression generates distinct senescent states with different Tp53 dependencies.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Senescence is a pleiotropic phenotype that alternatively suppresses or promotes cancer. Tumor-suppressive roles are attributed to irreversible cell cycle arrest and immune clearance, while tumor-promoting functions include apoptosis resistance and immune evasion, allowing cells to persist and support the tumor microenvironment or escape senescence and proliferate. Epigenetic changes are common features of senescent cells, and we used a preneoplastic liver cancer model caused by overexpression of the epigenetic regulator, UHRF1, in zebrafish hepatocytes to investigate how epigenome repatterning generates diverse senescent phenotypes. Early responses to UHRF1 overexpression include DNA damage, DNA methylome repatterning, retrotransposon derepression, cell cycle withdrawal, and atm and tp53-dependent senescence. scRNAseq analysis uncovers distinct senescent cell populations, some expressing immunogenic and anti-apoptotic genes, and others expressing proliferation genes. These populations have different capacities and susceptibilities based on UHRF1 levels. Cells with low UHRF1 levels proliferate in tp53 mutants, while cells with high UHRF1 levels do not re-enter the cell cycle and are targeted by the senolytic Navitoclax. This indicates that UHRF1 expression level can generate diverse senescent cell phenotypes with divergent outcomes.
Identifiers
42806154What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.